A phase II study of QX-002N in patients with ankylosing spondylitis
Latest Information Update: 20 Feb 2023
At a glance
- Drugs QX 002N (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Qyuns Therapeutics
- 20 Feb 2023 New trial record